COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).
IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.
For procurement cost of COMETRIQ™ (cabozantinib) capsules brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Lynparza (olaparib) tablets cost price in India.
The order for COMETRIQ™ (cabozantinib) capsules will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Cabozantinib, sold under the brand-name Cabometyx and Cometriq, is a medication used to treat medullary thyroid cancer and a second line treatment for renal cell carcinoma among others. It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET.
COMETRIQ™ (cabozantinib) capsules, for oral use Initial U.S. Approval: 2012
Generic Name: cabozantinib
20 mg and 80 mg capsules.
IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand COMETRIQ™ (cabozantinib) capsules on prescription and Import License in Patient's Name only.
For overseas patients, COMETRIQ™ (cabozantinib) capsules can be made available in Send your enquiry to find COMETRIQ™ (cabozantinib) capsules in China, Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong. UAE Iraq, Iran, Saudi Arabia, Jordan, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela. Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia. Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia, Algeria, Mauritius, Uganda, Zimbabwe. Australia and New Zealand.
For COMETRIQ™ (cabozantinib) capsules Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
Cabozantinib Now Also FDA Approved for Liver Cancer For More Details
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
Dated: APRIL 3, 2018